Helping Women Stay On Track With Breast Cancer Oral Medication
Part of Cancer clinical trials.
This study helps women with early-stage hormone-receptor-positive breast cancer take their oral medication (abemaciclib) consistently and correctly. The goal is to improve how well women stick with this treatment by offering support and education.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You have early-stage breast cancer that is hormone-receptor-positive and HER2-negative (a specific type)
- You started taking abemaciclib (a pill-based cancer medicine) combined with hormone therapy within the last 28 days
- Your doctor prescribed abemaciclib according to standard guidelines and your hospital's practices
- You are not pregnant or breastfeeding
- You do not have serious health conditions that would make it unsafe for you to take abemaciclib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
This study tests whether a coaching program based on personality types helps women with early-stage hormone receptor-positive, HER2-negative breast cancer stick to their treatment plan. Participants must be taking ribociclib (Kisqali) and an aromatase inhibitor, and their cancer must not have spread to other organs.
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
This study tests whether gradually increasing doses of a drug called abemaciclib, combined with hormone therapy, can safely treat early-stage breast cancer that is hormone-positive and HER2-negative. The goal is to find the best dose that works without causing too many side effects.
This trial tests whether the drug abemaciclib can help women with hormone receptor-positive, HER2-negative breast cancer who still have signs of cancer DNA in their blood after standard treatment. It aims to prevent a future return of the cancer.
This study uses real-world health records to learn about outcomes in people with hormone-receptor positive, HER2-negative breast cancer who were treated with abemaciclib along with hormone (endocrine) therapy. It may help doctors better understand how well this treatment works outside of clinical trials.
Hear when a new HR+/HER2- Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.